TuttleRM, TalaH, ShahJ, Leboeuf, GhosseinR, GonenM, BrokinM, OmryG, FaginJ, ShahaA. 2010. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid, 20:1341–1349.
2.
Klubo-GwiezdzinskaJ, BurmanKD, Van NostrandD, Wartofsky L 2011 Does an undetectable rh-TSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?. Clin Endocrinol (Oxf), 74:111–117.
3.
GiovanellaL, ClarkPM, ChiovatoL, DuntasL, EliseiR, Feldt-RasmussenU, LeenhardtL, LusterM, Schalin-JanttiC, SchottM, SeregniE, RimmeleH, SmitJ, VerburgFA. 2014. Thyroglobulin measurements using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol, 171:R33–R46.
4.
United States. Thyrogen Product Insert. Version approved March 2014.
5.
HaugenBR, PaciniF, ReinersC, SchlumbergerM, LadensonPW, ShermanSI, CooperDS, GrahamKE, BravermanLE, SkarulisMC, DaviesTF, DeGrootLJ, MazzaferriEL, DanielsGH, RossDS, LusterM, SamuelsMH, BeckerDV, MaxonHRIII, CavalieriRR, SpencerCA, McEllinK, WeintraubBD, RidgwayEC. 1999. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. JCEM, 84:3877–3885.
6.
Thyrogen, Genzyme Corp. Final Report. Protocol No. TSH95-0101.
